吉西他滨
癌症研究
生物
肿瘤微环境
免疫抑制
转录组
化疗
癌症
免疫学
生物化学
基因
基因表达
肿瘤细胞
遗传学
作者
Junlei Zhang,Juan Song,Shima Tang,Yaxing Zhao,Sheng Wang,Yandong Luo,Jianghui Tang,Yongtao Ji,X. Wang,Taohong Li,Hui Zhang,Wei Shao,Jianpeng Sheng,Tingbo Liang,Xueli Bai
出处
期刊:Cell Reports
[Elsevier]
日期:2023-06-01
卷期号:42 (6): 112620-112620
被引量:13
标识
DOI:10.1016/j.celrep.2023.112620
摘要
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer that typically demonstrates resistance to chemotherapy. Tumor-associated macrophages (TAMs) are essential in tumor microenvironment (TME) regulation, including promoting chemoresistance. However, the specific TAM subset and mechanisms behind this promotion remain unclear. We employ multi-omics strategies, including single-cell RNA sequencing (scRNA-seq), transcriptomics, multicolor immunohistochemistry (mIHC), flow cytometry, and metabolomics, to analyze chemotherapy-treated samples from both humans and mice. We identify four major TAM subsets within PDAC, among which proliferating resident macrophages (proliferating rMφs) are strongly associated with poor clinical outcomes. These macrophages are able to survive chemotherapy by producing more deoxycytidine (dC) and fewer dC kinases (dCKs) to decrease the absorption of gemcitabine. Moreover, proliferating rMφs promote fibrosis and immunosuppression in PDAC. Eliminating them in the transgenic mouse model alleviates fibrosis and immunosuppression, thereby re-sensitizing PDAC to chemotherapy. Consequently, targeting proliferating rMφs may become a potential treatment strategy for PDAC to enhance chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI